1. Home
  2. NABL vs GLUE Comparison

NABL vs GLUE Comparison

Compare NABL & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo N-able Inc.

NABL

N-able Inc.

HOLD

Current Price

$7.18

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$24.44

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NABL
GLUE
Founded
2000
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NABL
GLUE
Price
$7.18
$24.44
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$9.31
$27.00
AVG Volume (30 Days)
814.4K
2.4M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
$497,665,000.00
$181,538,000.00
Revenue This Year
$11.18
$84.02
Revenue Next Year
$8.73
N/A
P/E Ratio
N/A
$100.27
Revenue Growth
8.65
1112.27
52 Week Low
$6.07
$3.50
52 Week High
$10.41
$25.77

Technical Indicators

Market Signals
Indicator
NABL
GLUE
Relative Strength Index (RSI) 41.74 72.34
Support Level $7.07 $13.69
Resistance Level $7.48 $25.77
Average True Range (ATR) 0.21 1.51
MACD -0.02 0.84
Stochastic Oscillator 22.22 89.74

Price Performance

Historical Comparison
NABL
GLUE

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: